Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$30.09 +5.7%	$30.42	$24.10 ▼ $62.53	$2.83B	0.33	944,896 shs	989,067 shs
KYMR Kymera Therapeutics	$40.73 +2.2%	$44.93	$19.44 ▼ $53.27	$2.65B	2.18	747,285 shs	830,892 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
XERS Xeris Biopharma	$7.28 -0.3%	$5.05	$2.39 ▼ $7.61	$1.17B	0.65	2.57 million shs	2.67 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	+4.02%	-2.60%	-10.80%	-8.98%	-42.55%
KYMR Kymera Therapeutics	+5.81%	-7.21%	-10.36%	+34.02%	-6.19%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
XERS Xeris Biopharma	+1.39%	+33.21%	+42.86%	+57.33%	+224.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRNX Crinetics Pharmaceuticals	3.4168 of 5 stars	3.4	0.0	0.0	3.7	2.3	2.5	0.0
KYMR Kymera Therapeutics	3.0833 of 5 stars	4.6	3.0	0.0	0.0	1.0	2.5	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	2.9016 of 5 stars	1.4	1.0	0.0	4.2	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.78	Moderate Buy	$68.86	128.84% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	45.13% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
XERS Xeris Biopharma	2.83	Moderate Buy	$6.58	-9.51% Downside

Current Analyst Ratings Breakdown

Latest XERS, KYMR, MOR, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
8/11/2025	CRNX Crinetics Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$90.00 ➝ $86.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$1.39M	2,035.74	N/A	N/A	$12.44 per share	2.42
KYMR Kymera Therapeutics	$47.07M	56.35	N/A	N/A	$12.90 per share	3.16
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
XERS Xeris Biopharma	$246.03M	4.77	N/A	N/A	($0.12) per share	-60.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$298.41M	-$4.11	N/A	N/A	N/A	N/A	-32.28%	-29.45%	N/A
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-616.03%	-32.86%	-28.19%	10/30/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
XERS Xeris Biopharma	-$54.84M	-$0.21	N/A	N/A	N/A	-13.01%	N/A	-8.00%	N/A

Latest XERS, KYMR, MOR, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/7/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	-$1.23	-$0.10	-$1.23	$0.52 million	$1.03 million
8/7/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	-$0.01	+$0.02	-$0.01	$64.58 million	$67.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	17.80	17.80
KYMR Kymera Therapeutics	N/A	8.49	8.49
MOR MorphoSys	4.98	1.38	1.38
XERS Xeris Biopharma	N/A	1.95	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	4.60%
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%
XERS Xeris Biopharma	4.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	94.18 million	88.53 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
XERS Xeris Biopharma	290	161.48 million	154.12 million	Optionable

XERS, KYMR, MOR, and CRNX Headlines

Recent News About These Companies

Xeris Biopharma's (XERS) "Buy" Rating Reaffirmed at HC Wainwright

August 13 at 8:35 AM | marketbeat.com

Informed Momentum Co LLC Grows Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 13 at 6:27 AM | marketbeat.com

Xeris Biopharma assumed with a Buy at H.C. Wainwright

August 12 at 5:49 PM | msn.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

August 12 at 1:01 PM | zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

August 12 at 10:16 AM | zacks.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Knott David M Jr's 7th Largest Position

August 12 at 8:17 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street Zen

August 11 at 2:59 AM | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Expectations By $0.02 EPS

August 10 at 12:37 AM | marketbeat.com

Critical Survey: Xeris Biopharma (NASDAQ:XERS) versus CASI Pharmaceuticals (NASDAQ:CASI)

August 10 at 3:23 AM | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Upgraded to "Strong-Buy" at Wall Street Zen

August 10 at 2:49 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume After Better-Than-Expected Earnings

August 10 at 2:43 AM | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume Following Better-Than-Expected Earnings

August 9, 2025 | marketbeat.com

Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations

August 9, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Earnings Beat

August 9, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Strong Earnings

August 8, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 7, 2025 | zacks.com

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

August 7, 2025 | finance.yahoo.com

Federated Hermes Inc. Purchases 685,906 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 5, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Increase in Short Interest

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XERS, KYMR, MOR, and CRNX Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.09 +1.61 (+5.65%)

Closing price 04:00 PM Eastern

Extended Trading

$29.70 -0.39 (-1.30%)

As of 04:10 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Kymera Therapeutics NASDAQ:KYMR

$40.73 +0.86 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$40.78 +0.05 (+0.11%)

As of 04:20 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/11/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Xeris Biopharma NASDAQ:XERS

$7.28 -0.03 (-0.34%)

Closing price 03:59 PM Eastern

Extended Trading

$7.28 +0.00 (+0.07%)

As of 04:10 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time